MedTrace Logo

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

NCT01791686 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2014-03-07

No results posted yet for this study

Summary

This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.

Conditions

  • Dense Deposit Disease
  • Membranoproliferative Glomerulonephritis Type II
  • C3 Glomerulonephritis

Interventions

DRUG

CDX-1135

Sponsors & Collaborators

  • Celldex Therapeutics

    lead INDUSTRY

Principal Investigators

  • Carla Nester, MD, MSA · University of Iowa

  • Richard Smith, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01791686 on ClinicalTrials.gov